24小时热门版块排行榜    

CyRhmU.jpeg
查看: 119  |  回复: 0
当前主题已经存档。

abcd888898

银虫 (正式写手)

[交流] 【转帖】Roche provides update on phase III study of Avastin

Roche provides update on phase III study of Avastin in men with late stage prostate cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone. A preliminary assessment of safety performed by CALGB has shown adverse events that have been previously observed in pivotal trials with Avastin. Data from the study will be submitted by CALGB for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010.

“Patients with hormone-refractory prostate cancer are in urgent need of new treatment options. It is unfortunate that the study did not meet its primary objective, however, we look forward to sharing the data with the medical community, including the secondary endpoints,” said Hal Barron, M.D., Head Global Development and Chief Medical Officer at Roche.

These findings do not impact Avastin’s approved indications, where Avastin has made anti-angiogenic therapy a fundamental pillar of cancer treatment. Avastin’s broad development programme in other tumour types will also continue as planned.
回复此楼
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 abcd888898 的主题更新
普通表情 高级回复(可上传附件)
信息提示
请填处理意见